Seres Therapeutics, Inc. (MCRB)
| Market Cap | 68.56M |
| Revenue (ttm) | 1.15M |
| Net Income (ttm) | -46.90M |
| Shares Out | 9.68M |
| EPS (ttm) | -5.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 301,442 |
| Open | 6.85 |
| Previous Close | 6.85 |
| Day's Range | 6.85 - 7.57 |
| 52-Week Range | 5.31 - 29.98 |
| Beta | 0.11 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+140.79%) |
| Earnings Date | Aug 5, 2026 |
About MCRB
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MCRB stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 140.79% from the latest price.
News
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line res...
Seres Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Seres Therapeutics (MCRB) with a Buy rating and $12 price target Seres is a clinical stage biotech company developing live biotherapeutic products for inflammator...
Seres Therapeutics announces two transactions
Seres Therapeutics (MCRB) announced two transactions to extend its expected operating cash runway well into the first quarter of 2027. Seres entered into an amendment to the prior asset purchase…
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones
Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The presentation highlighted advances in microbiome-based therapeutics, including a phase II-ready asset with strong efficacy data and the integration of generative AI into drug development. Near-term milestones include key clinical readouts and strategic partnerships, with a focus on high-need patient populations.
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biother...
Seres Therapeutics Earnings release: Q1 2026
Seres Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Seres Therapeutics Quarterly report: Q1 2026
Seres Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar...
Seres Therapeutics Proxy statement: Proxy filing
Seres Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Seres Therapeutics Proxy statement: Proxy filing
Seres Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Seres Therapeutics announces three presentations at 2026 ESCMID congress
Seres Therapeutics (MCRB) announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases, ESCMID, global congress, taking place April 17-21 in Munich, Germ...
Seres Therapeutics announces three presentations at 2026 ESCMID congress
Seres Therapeutics (MCRB) announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases, ESCMID, global congress, taking place April 17-21 in Munich, Germ...
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
Seres Therapeutics to Present at CARB-X Investor Day
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at th...
Seres Therapeutics Annual report: Q4 2025
Seres Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Seres Therapeutics Earnings release: Q4 2025
Seres Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Seres Therapeutics reports FY25 EPS 64c
Reports FY25 revenue $789k. “As highlighted in our recent announcements, we are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER-603 for inflammatory bow...
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track fo...
Seres Therapeutics Transcript: Status update
Management transitions and a focused strategy are driving live biotherapeutic programs in inflammatory and immune diseases. Key clinical milestones include an upcoming SER-155 irEC data readout and ongoing development of SER-603 for IBD. Cash runway extends through Q3 2026.
Seres Therapeutics Earnings release: Status update
Seres Therapeutics released its earnings on March 3, 2026, summarizing the period's financial results.
Seres co-CEOs Tom DesRosier, Marella Thorell to step down
Seres Therapeutics (MCRB) announced the appointment of Richard Kender as executive chair and interim CEO. Kender has served on the Seres board of directors since September 2014. Tom DesRosier and…
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs...
Seres pauses investment in SER-155 program, reports workforce reduction of 30%
Seres Therapeutics (MCRB) announced that, following advancement of key startup activities for the SER-155 Phase 2 study in allo-HSCT, including the submission of a final protocol to the FDA, study…